Menu
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2023 Sustainability Report. The report highlights the company’s continued commitment and progress on its key corporate sustainability initiatives. The Sustainability Jetzt den vollständigen Artikel lesen
https://www.investing.com/news/company-news/glaukos-corp-executive-sells-over-6-million-in-company-stock-93CH-3374099
Glaukos Corp CFO Alex Thurman Sells Company Shares
https://www.investing.com/news/company-news/glaukos-corp-president--coo-sells-386k-in-stock-93CH-3368310
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for iDose TR (travoprost intracameral implant) Jetzt den vollständigen Artikel lesen
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA. Glaukos will Jetzt den vollständigen Artikel lesen
Celanese Corporation collaborates with Glaukos Corporation to launch iDose® TR, a sustained drug release system for glaucoma treatment. The FDA-approved iDose® TR uses Celanese''s VitalDose® EVA to deliver continuous dosing of travoprost, improving patient compliance and treatment outcomes.
Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, announced the launch of iDose TR by Glaukos Corporation using Celanese’s VitalDose EVA to provide sustained drug release for the treatment of glaucoma. The majority of glaucoma and ocular hypertension patients are non-compliant with topical medication use due to complex dosing regiments, side effects, and eye-drop Jetzt den vollständigen Artikel lesen
